Heart Test Laboratories, Inc.

Equities

HSCS

US42254E1047

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
0.0861 ^USD	-3.04%		-10.68%	-49.65%

Apr. 24	HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG	CI
Mar. 26	HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients	CI

Heart Test Laboratories, Inc. announced that it has received $1 million in funding

September 19, 2023

On September 20, 2023, Heart Test Laboratories, Inc. closed the transaction. The company raised $750,000 in its second and final tranche. The company raised a total of $1,000,000 in the transaction from single investor.

Latest news about Heart Test Laboratories, Inc.

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG	Apr. 24	CI
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients	Mar. 26	CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 14	CI
Heart Test Laboratories, Inc. Appoints Partho P. Sengupta to Its Scientific Advisory Board	Feb. 26	CI
Heart Test Laboratories, Inc. Appoints Jordan B. Strom to Its Scientific Advisory Board	Feb. 12	CI
HeartSciences Appoints Benjamin Glicksberg to its Scientific Advisory Board	Feb. 01	CI
Heart Test Laboratories, Inc. has Changed its Name to HeartSciences Inc	Jan. 17	CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 14	CI
Heart Test Laboratories, Inc. announced that it has received $0.934997 million in funding	Dec. 06	CI
Heart Test Laboratories, Inc. announced that it has received $1.085006 million in funding	Dec. 06	CI
Heart Test Laboratories, Inc. Enters into Multiple Definitive License Agreements with Icahn School of Medicine At Mount Sinai	Dec. 06	CI
HeartSciences Completes License Agreements on AI Cardiovascular Algorithms With Icahn School of Medicine at Mount Sinai	Nov. 20	MT
Heart Test Laboratories, Inc. announced that it expects to receive $0.934997 million in funding	Nov. 15	CI
Heart Test Laboratories, Inc. announced that it expects to receive $1.085006 million in funding	Nov. 14	CI
Heart Test Laboratories, Inc. Announces That Its Myovista® Wavecgtm Has Been Selected by Cardiact Ltd (?Cardiact?) to Be Used in Its Heart Screening Program of Members of the Association of Garda Sergeants and Inspectors	Nov. 13	CI
Heart Test Laboratories, Inc. announced that it has received $1 million in funding	23-09-19	CI
Sector Update: Health Care Stocks Lower Late Afternoon	23-09-18	MT
Sector Update: Health Care Stocks Mixed Monday Afternoon	23-09-18	MT
Heart Test Laboratories Files for $50 Million Mixed Shelf; Shares Drop	23-09-18	MT
Heart Test Laboratories, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-14	CI
Heart Test Laboratories, Inc. announced that it expects to receive $1 million in funding	23-09-06	CI
Heart Test Laboratories Has Distribution Accord With Denmark's FJ Medical	23-08-31	MT
Heart Test's MyoVista wavECG Selected by PanaceaFlo for Heart Screening Evaluation Study in Dublin	23-08-24	MT
Heart Test Laboratories, Inc. Announces It?s MyoVista wavECGTM Selection to Be Used in Irish Heart Screening Evaluation	23-08-24	CI
Heart Test Laboratories Gets Patent Allowance Notice From European Patent Office	23-08-17	MT

Chart Heart Test Laboratories, Inc.

Duration

Period

More charts

Company Profile

Heart Test Laboratories, Inc., doing business as HeartSciences, is an artificial intelligence electrocardiogram (AI ECG) company. The Company is focused on using AI to transform ECG to save lives through earlier detection of heart disease. The Companyâs initial focus is on applying technology to extend the clinical indications for use of an electrocardiograph (ECG) device. Its first device, the MyoVista is an ECG that can be used in a range of clinical settings and provides diagnostic information to a qualified healthcare professional on cardiac dysfunction which has traditionally only been provided using cardiac imaging. In addition, MyoVista provides conventional ECG information. The Company focuses on marketing its device both domestically and internationally to various hospitals, clinics, and medical centers and manufacturing the devices using outsourced production facilities.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-16 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Heart Test Laboratories, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0861 USD

Average target price

0.675 USD

Spread / Average Target

+683.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Monitoring Systems

	1st Jan change	Capi.
HEART TEST LABORATORIES, INC.	-49.65%	5.82M
EKF DIAGNOSTICS HOLDINGS PLC	-5.53%	170M
MEDIANA CO.,LTD	-14.17%	84.67M
NEUROTECH INTERNATIONAL LIMITED	+17.39%	61.22M

Medical Monitoring Systems